{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=9", "query": { "intervention": "Placebo SC Injection", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 833, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T06:40:11.864Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06072157", "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants", "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "AK006-IV", "type": "DRUG" }, { "name": "Placebo-IV", "type": "DRUG" }, { "name": "AK006-SC", "type": "DRUG" }, { "name": "Placebo-SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 136, "start_date": "2023-08-28", "completion_date": "2025-05-12", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 19, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072157" }, { "nct_id": "NCT03105128", "title": "A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "placebo for risankizumab", "type": "DRUG" }, { "name": "risankizumab IV", "type": "DRUG" }, { "name": "risankizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 931, "start_date": "2017-05-10", "completion_date": "2021-04-14", "has_results": true, "last_update_posted_date": "2022-07-06", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 117, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03105128" }, { "nct_id": "NCT04083222", "title": "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "ISIS 757456", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 26, "start_date": "2019-11-13", "completion_date": "2020-07-20", "has_results": true, "last_update_posted_date": "2023-01-18", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Los Angeles, California • Tustin, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083222" }, { "nct_id": "NCT01474512", "title": "A Phase 3 Study in Participants With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "80 mg Ixekizumab Dosing Regimens 1, 2, and 3", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1296, "start_date": "2011-11-16", "completion_date": "2018-09-20", "has_results": true, "last_update_posted_date": "2019-10-03", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01474512" }, { "nct_id": "NCT05623345", "title": "Psoriatic Arthritis Study of Izokibep", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Izokibep", "type": "DRUG" }, { "name": "Placebo to izokibep", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ACELYRIN Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 351, "start_date": "2022-11-21", "completion_date": "2024-08-08", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 40, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05623345" }, { "nct_id": "NCT03238781", "title": "Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Migraine or Episodic Migraine" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "AMG 301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 343, "start_date": "2017-09-06", "completion_date": "2019-02-04", "has_results": true, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 21, "location_summary": "Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "East Hartford", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03238781" }, { "nct_id": "NCT01663402", "title": "ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LMT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 18924, "start_date": "2012-10", "completion_date": "2018-01-23", "has_results": true, "last_update_posted_date": "2019-03-18", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 273, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663402" }, { "nct_id": "NCT02836496", "title": "Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypereosinophilic Syndrome" ], "interventions": [ { "name": "Mepolizumab 300 mg", "type": "DRUG" }, { "name": "Placebo matching mepolizumab", "type": "DRUG" }, { "name": "Active OCS capsules (5 mg prednisolone or prednisone)", "type": "DRUG" }, { "name": "Placebo matching OCS capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 108, "start_date": "2017-03-07", "completion_date": "2019-08-08", "has_results": true, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 7, "location_summary": "San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Mayfield Heights", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02836496" }, { "nct_id": "NCT00791479", "title": "Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2189265 and Lifestyle Measures", "type": "DRUG" }, { "name": "Placebo solution and Lifestyle Measures", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 167, "start_date": "2008-12", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2014-12-10", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 12, "location_summary": "Concord, California • Lancaster, California • Mission Hills, California + 9 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Vincennes", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00791479" }, { "nct_id": "NCT07783542", "title": "ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa (HS)" ], "interventions": [ { "name": "ORKA-002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Oruka Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 200, "start_date": "2026-08-21", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-10-30T06:40:11.864Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Cromwell", "state": "Connecticut" }, { "city": "Sandy Springs", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07783542" } ] }